The U.S. Food and Drug Administration (FDA) has responded to Vanda Pharmaceuticals’ persistent requests for a public hearing regarding the proposed expansion of its Hetlioz label to include treatment for jet lag. This development comes after the drug was initially rejected in 2019, marking a significant moment for the company that has sought to address the regulatory body’s concerns for over four years.
Vanda’s advocacy for this hearing underscores the challenges pharmaceutical companies face in navigating the regulatory landscape, particularly when seeking to expand indications for existing therapies. The FDA’s decision to hold a formal hearing indicates a willingness to engage in dialogue about the potential benefits and risks associated with Hetlioz for jet lag, which could set a precedent for future submissions.
Should the hearing yield favorable outcomes for Vanda, it may not only revive the prospects for Hetlioz but also enhance the company’s credibility within the industry. This case highlights the importance of regulatory engagement and the potential for companies to influence the approval process through sustained advocacy efforts.
Start your 7-day trial and see what the database can do →
